Vasoactive intestinal peptide balances pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal perforation

Journal of Immunology

Volumn 178, Issue 2, 2007, Pages 1105-1114

  Szliter, Elizabeth A ^a   Lighvani, Shahrzad ^a   Barrett, Ronald P ^a   Hazlett, Linda D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 2; MESSENGER RNA; NITRIC OXIDE; PHOSPHATE BUFFERED SALINE; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CELL STIMULATION; CONTROLLED STUDY; CORNEA OPACITY; CORNEA PERFORATION; ENZYME IMMUNOASSAY; FEMALE; IMMUNOCYTOCHEMISTRY; IMMUNOREGULATION; INFECTION RESISTANCE; INFLAMMATORY CELL; KERATITIS; MACROPHAGE; MOUSE; NERVE FIBER; NEUTROPHIL COUNT; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE;

EID: 33846212299     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.2.1105     Document Type: Article

References (37)

1. Hazlett, L. D. 2004. Corneal response to Pseudomonas aeruginosa infection. Prog. Retin. Eye Res. 23: 1-30.
2. Hazlett, L. D., S. McClellan, B. Kwon, and R. Barrett. 2000. Increased severity of Pseudomonas aeruginosa corneal infection in strains of mice designated as Th1 versus Th2 responsive. Invest. Ophthalmol. Vis. Sci. 41: 805-810.
3. Lighvani, S., X. Huang, P. P. Trivedi, R. H. Swanborg, and L. D. Hazlett. 2005. Substance P regulates natural killer cell interferon-γ production and resistance to Pseudomonas aeruginosa infection. Eur. J. Immunol. 35: 1567-1575.
4. Muller, L. J., C. F. Marfurt, F. Kruse, and T. M. Tervo. 2003. Corneal nerves: structure, contents and function. Exp. Eye Res. 76: 521-542.
5. Delgado, M., D. Pozo, and D. Ganea. 2004. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56: 249-290.
6. Harmar, A. J., A. Arimura, I. Gozes, L. Journot, M. Laburthe, J. R. Pisegna, S. R. Rawlings, P. Robberecht, S. I. Said, S. P. Sreedharan, et al. 1998. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol. Rev. 50: 265-270.
7. Pozo, D., and M. Delgado. 2004. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J. 18: 1325-1334.
8. Delgado, M., and D. Ganea. 2001. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J. Immunol. 166: 2907-2912.
9. Rudner, X. L., K. A. Kernacki, R. P. Barrett, and L. D. Hazlett. 2000. Prolonged elevation of IL-1 in Pseudomonas aeruginosa ocular infection regulates macrophage-inflammatory protein-2 production, polymorphonuclear neutrophil persistence, and corneal perforation. J. Immunol. 164: 6576-6582.
10. Hazlett, L. D., M. M. Moon, M. Strejc, and R. S. Berk. 1987. Evidence for N-acetylmannosamine as an ocular receptor for P. aeruginosa adherence to scarified cornea. Invest. Ophthalmol. Vis. Sci. 28: 1978-1985.
11. Williams, R. N., C. A. Paterson, K. E. Eakins, and P. Bhattacherjee. 1982. Quantification of ocular inflammation: evaluation of polymorphonuclear leucocyte infiltration by measuring myeloperoxidase activity. Curr. Eye Res. 2: 465-470.
12. Roux, K. H. 1995. Optimization and troubleshooting in PCR. PCR Methods Appl. 4: S185-S194.
13. Fortier, A. H. 1994. Isolation of murine macrophages. In Current Protocols in Immunology. John Wiley and Sons, New York, pp. 14.11.11-14.11.16.
14. Luo, Y. a. M. E. D. 1997. Isolation of mouse neutrophils. In Current Protocols in Immunology. John Wiley and Sons, New York, pp. 3.20.21-23.20.26.
15. Delgado, M., E. J. Munoz-Elias, C. Martinez, R. P. Gomariz, and D. Ganea. 1999. VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. Ann. NY Acad. Sci. 897: 401-414.
16. Delgado, M., E. J. Munoz-Elias, R. P. Gomariz, and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J. Immunol. 162: 1707-1716.
17. Hazlett, L. D., X. L. Rudner, S. A. McClellan, R. P. Barrett, and S. Lighvani. 2002. Role of IL-12 and IFN-γ in Pseudomonas aeruginosa corneal infection. Invest. Ophthalmol. Vis. Sci. 43: 419-424.
18. Delgado, M., E. J. Munoz-Elias, R. P. Gomariz, and D. Ganea. 1999. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages: subsequent effect on IFNγ synthesis by T cells. J. Neuroimmunol. 96: 167-181.
19. Martinez, C., M. Delgado, D. Pozo, J. Leceta, J. R. Calvo, D. Ganea, and R. P. Gomariz. 1998. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J. Neuroimmunol. 85: 155-167.
20. Henning, R. J., and D. R. Sawmiller. 2001. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc. Res. 49: 27-37.
21. Koh, S. W., A. Rutzen, T. Coll, R. Hemady, and E. Higginbotham. 2005. VIP immunoreactivity in human aqueous humor. Curr. Eye Res. 30: 189-194.
22. Delgado, M., E. J. Munoz-Elias, R. P. Gomariz, and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and IFN regulatory factor 1 activation. J. Immunol. 162: 4685-4696.
23. Delgado, M., C. Abad, C. Martinez, J. Leceta, and R. P. Gomariz. 2001. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7: 563-568.
24. McClellan, S. A., X. Huang, R. P. Barrett, N. van Rooijen, and L. D. Hazlett. 2003. Macrophages restrict Pseudomonas aeruginosa growth, regulate polymorphonuclear neutrophil influx, and balance pro- and anti-inflammatory cytokines in BALB/c mice. J. Immunol. 170: 5219-5227.
25. Delgado, M., C. Martinez, D. Pozo, J. R. Calvo, J. Leceta, D. Ganea, and R. P. Gomariz. 1999. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J. Immunol. 162: 1200-1205.
26. Liew, F. Y., Y. Li, D. Moss, C. Parkinson, M. V. Rogers, and S. Moncada. 1991. Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophages. Eur. J. Immunol. 21: 3009-3014.
27. Su, S. H., H. Chen, and C. J. Jen. 2001. C57BL/6 and BALB/c bronchoalveolar macrophages respond differently to exercise. J. Immunol. 167: 5084-5091.
28. Waring, G. O., 3rd, and M. M. Rodrigues. 1987. Patterns of pathologic response in the cornea. Surv. Ophthalmol. 31: 262-266.
29. Hazlett, L. D., D. D. Rosen, and R. S. Berk. 1977. Pseudomonas eye infections in cyclophosphamide-treated mice. Invest. Ophthalmol. Vis. Sci. 16: 649-652.
30. Thiel, H. J., K. P. Steuhl, and G. Doring. 1987. Therapy of Pseudomonas aeruginosa eye infections. Antibiot. Chemother. 39: 92-101.
31. Delgado, M., and D. Ganea. 2001. Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Arch. Physiol. Biochem. 109: 377-382.
32. Delgado, M., and D. Ganea. 2003. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochem. Biophys. Res. Commun. 301: 825-832.
33. Voice, J. K., G. Dorsam, R. C. Chan, C. Grinninger, Y. Kong, and E. J. Goetzl. 2002. Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide. Regul. Pept. 109: 199-208.
34. Hazlett, L. D. 2002. Pathogenic mechanisms of P. aeruginosa keratitis: a review of the role of T cells, Langerhans cells, PMN, and cytokines. DNA Cell Biol. 21: 383-390.
35. + T cell chemotaxis and indirectly enhances PMN persistence in Pseudomonas aeruginosa corneal infection. J. Leukocyte Biol. 70: 911-919.
36. Delgado, M. 2003. VIP: a very important peptide in T helper differentiation. Trends Immunol. 24: 221-224.
37. Streilein, J. W., and J. Stein-Streilein. 2000. Does innate immune privilege exist? J. Leukocyte Biol. 67: 479-487.